Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761496 | 0.91 | CYP3A4 (0.43) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9811267 | 0.81 | TSHR (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9865407 | 0.81 | TSHR (0.39) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL2843185 | 0.78 | — | — | |
| SCHEMBL9865572 | 0.77 | CYP3A4 (0.37) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL13861279 | 0.75 | TSHR (0.42) | CYP3A4TSHRMAPTCACNA1BAPBA1 | |
| SCHEMBL9865182 | 0.75 | CYP3A4 (0.49) | CYP3A4TSHRMAPTALDH1A1HSD17B10 | |
| SCHEMBL9543820 | 0.75 | — | — | |
| SCHEMBL9413861 | 0.75 | — | — | |
| SCHEMBL175470 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105358136-B | Supermolecule magnetic nano-particle | 加利福尼亚大学董事会 | 2018-11-13 | — | — | CN | disclosed |
| CN-105358136-A | Supramolecular magnetic nanoparticles | UNIV CALIFORNIA | 2016-02-24 | — | — | CN | disclosed |
| EP-1642932-B1 | CURING COMPOSITION | KANEKA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| EP-1277804-B1 | CURABLE COMPOSITIONS | KANEKA CORP (JP) | 2011-08-17 | — | — | EP | disclosed |
| EP-1961786-B1 | CURABLE COMPOSITION FOR DAMPING MATERIAL AND DAMPING MATERIAL | KANEKA CORP (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20090292075-A1 | CURABLE COMPOSITION FOR DAMPING MATERIAL AND DAMPING MATERIAL | KANEKA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20080234426-A1 | Curable Composition and Cured Object Thereof | KANEKA CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| EP-1961786-A1 | CURABLE COMPOSITION FOR DAMPING MATERIAL AND DAMPING MATERIAL | Kaneka Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20070276066-A1 | Curing Composition | KANEKA CORPORATION (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1526155-A1 | MOLD-RELEASABLE CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2005-04-27 | — | — | EP | disclosed |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | AVENTIS PHARMA S.A. (FR) | 2005-01-13 | — | — | US | disclosed |
| US-20030166795-A1 | Curable compositions | KANEKA CORPORATION (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1277804-A1 | CURABLE COMPOSITIONS | KANEKA CORPORATION (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-5066825-A | Antilipemic agents | TANABE SEIYAKU CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| EP-0379935-A1 | A process for preparing naphthalene derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-01 | — | — | EP | disclosed |
| EP-0371484-A2 | A process for preparing a naphthalene derivative | TANABE SEIYAKU CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
| US-4558069-A | TREATMENT OF SKIN DISORDERS | GROUPEMENT D'INTERET ECONOMIQUE DIT: CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1985-12-10 | — | — | US | disclosed |
| US-4464301-A | FOR TREATMENT OF PSORIASIS | GROUPEMENT D'INTERET ECONOMIQUE CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1984-08-07 | — | — | US | disclosed |
| US-4207318-A | ANTIALLERGIC ACTIVITY, BRONCHODILATOR | ROUSSEL UCLAF (FR) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125418-A1 | Benzimidazole derivatives and their use as kdr kinase protein inhibitors | KDR, MUSK, FLT4 | CYP3A4 1062/4885TSHR 532/4885MAPT 3744/4885 |
| US-20050009894-A1 | Benzimidazole derivatives and their use as KDR kinase protein inhibitors | KDR, MUSK, FLT4 | CYP3A4 1055/4885TSHR 517/4885MAPT 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.